Clinical trials
Antibody-mediated Rejection clinical trials
Below are recruiting antibody-mediated rejection clinical trials, each written for real people, not researchers. We’re tracking 9 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07444489Enrolling by invitationPhase 3
Long-term safety of felzartamab for kidney transplant rejection
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Los Angeles, CaliforniaAges 18–75 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT07663669Recruiting
Photopheresis for antibody-mediated rejection in kidney transplant
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
BesançonAges 18 years+ - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT06990711RecruitingPhase 1
Siltuximab for antibody-mediated rejection after lung transplant
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
St Louis, MissouriAges 18 years+ - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT06112951Recruiting
ECP treatment for early signs of lung transplant rejection
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
ViennaAges 18 years+ - NCT05004493Recruiting
Plasma exchange patient registry and sample collection
This study collects information and blood or other samples from people who are getting plasma exchange therapy. The goal is to build a registry (a organized database) that researchers can use to better understand and improve care.
Iowa City, IowaAges 12–99
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody-mediated rejection?
- Yes. Clin2 currently lists 9 recruiting antibody-mediated rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody-mediated rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody-mediated rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.